Research Hotspot

Glycoconjugate Vaccine

Composition and Immune Mechanism of Glycoconjugate Vaccine

A conjugate vaccine is a type of vaccine that combines a weak or non-toxic part of a disease-causing microorganism (such as a bacteria or virus) with a carrier protein. The […]

antibody drug conjugate

ADC Cleavable Linker: Classification and Mechanism of Action

Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances […]

Peptide-drug Conjugate

Overview of Peptide-drug Conjugate

The concept of drug conjugates originated in the early 20th century. In 1910, Paul Ehrlich proposed the “Magic Bullet” theory, which aimed to describe the concept of a drug that […]

antibody drug conjugate

FDA Approved Antibody-Drug Conjugates (ADCs) By 2023

Antibody Drug Conjugate (ADC) is a complex formed by linking cytotoxic drugs to tumor-targeting monoclonal antibodies. It combines the characteristics of targeted drugs and chemotherapy drugs to achieve precise treatment. The concept […]

drug discovery

Research Progress of Small Molecule Drugs Targeting PD-1/PD-L1

Immunotherapy, which uses immune pathways to treat cancer, is rapidly becoming an accepted cancer treatment after surgery, chemotherapy and radiation. Checkpoint blocking using monoclonal antibodies against cytotoxic T lymphocyte-associated protein […]

drug discovery

Advances in Research on Small Molecule Janus Kinase (JAK) Inhibitors

Janus kinases (JAKs) belong to the non-receptor tyrosine kinase family, and their JAK-STAT signaling pathway with signal transducers and activators of transcription (STAT) can affect cell proliferation, differentiation, apoptosis, and […]

lab experiment

FDA-approved small molecule kinase inhibitors-Part 3

Fostamatinib is the precursor drug of active metabolite R406. It is a Syk inhibitor with an IC50 value of 41 nM. It strongly inhibits Syk but does not inhibit Lyn. […]

drug research

FDA-approved small molecule kinase inhibitors-Part 2

Dabrafenib (GSK2118436) is a mutant BRAFV600-specific inhibitor, with an IC50 of 0.7 nM in cell-free assays. It shows 7-fold and 9-fold lower potency against B-Raf(wt) and c-Raf, respectively. Synthetic route: […]

drug development

FDA-approved small molecule kinase inhibitors-Part 1

Kinase inhibitors can be divided into monoclonal antibodies (mAbs) and small molecule kinase inhibitors (SMKIs) based on their structure and size. Monoclonal antibodies have achieved great success in the development […]

drugs

Marketed Nucleic Acid Drugs and Their Lipid Nano-Delivery Systems

Existing research shows that nucleic acids can be used for the treatment of neurological diseases, cardiovascular diseases, and cancer, as well as for the prevention of chronic and infectious diseases. […]